Black Rock Inc. Protagonist Therapeutics, Inc Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Black Rock Inc. holds 5,758,112 shares of PTGX stock, worth $234 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,758,112
Previous 5,569,485
3.39%
Holding current value
$234 Million
Previous $161 Million
23.83%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PTGX
# of Institutions
248Shares Held
56.7MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$238 Million1.32% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$220 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$171 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$129 Million0.01% of portfolio
-
Johnson & Johnson New Brunswick, NJ2.45MShares$99.4 Million35.09% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.99B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...